ID   VIME_HUMAN              Reviewed;         466 AA.
AC   P08670; B0YJC2; D3DRU4; Q15867; Q15868; Q15869; Q548L2; Q6LER9; Q8N850;
AC   Q96ML2; Q9NTM3;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   28-JAN-2026, entry version 279.
DE   RecName: Full=Vimentin {ECO:0000312|HGNC:HGNC:12692};
GN   Name=VIM {ECO:0000312|HGNC:HGNC:12692};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3467175; DOI=10.1128/mcb.6.11.3614-3620.1986;
RA   Ferrari S., Battini R., Kaczmarek L., Rittling S., Calabretta B.,
RA   de Riel J.K., Philiponis V., Wei J.-F., Baserga R.;
RT   "Coding sequence and growth regulation of the human vimentin gene.";
RL   Mol. Cell. Biol. 6:3614-3620(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2251132; DOI=10.1093/nar/18.22.6692;
RA   Honore B., Madsen P., Basse B., Andersen A., Walbum E., Celis J.E.,
RA   Leffers H.;
RT   "Nucleotide sequence of cDNA covering the complete coding part of the human
RT   vimentin gene.";
RL   Nucleic Acids Res. 18:6692-6692(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lymphoma;
RX   PubMed=14996095; DOI=10.1111/j.1365-2133.2004.05651.x;
RA   Hartmann T.B., Thiel D., Dummer R., Schadendorf D., Eichmueller S.;
RT   "SEREX identification of new tumour-associated antigens in cutaneous T-cell
RT   lymphoma.";
RL   Br. J. Dermatol. 150:252-258(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Testis;
RA   Zimbelmann R.;
RL   Submitted (JUN-2007) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Embryo, Placenta, and Stomach;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Adipose tissue, and Coronary artery;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (FEB-2007) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cervix, Placenta, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-135, AND TISSUE SPECIFICITY.
RC   TISSUE=Mammary carcinoma;
RX   PubMed=2472876;
RA   Sommers C.L., Walker-Jones D., Heckford S.E., Worland P., Valverius E.,
RA   Clark R., McCormick F., Stampfer M., Abularach S., Gelmann E.P.;
RT   "Vimentin rather than keratin expression in some hormone-independent breast
RT   cancer cell lines and in oncogene-transformed mammary epithelial cells.";
RL   Cancer Res. 49:4258-4263(1989).
RN   [13]
RP   PROTEIN SEQUENCE OF 2-11; 87-96; 129-138; 188-195; 223-234; 282-291;
RP   322-333 AND 381-389, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT
RP   SER-2, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=T-cell;
RA   Bienvenut W.V., Kanor S., Tissot J.-D., Quadroni M.;
RL   Submitted (MAY-2006) to UniProtKB.
RN   [14]
RP   PROTEIN SEQUENCE OF 5-12; 14-45; 51-64; 72-78; 105-113; 123-143; 159-184;
RP   187-217; 223-236; 271-292; 295-313; 322-390 AND 403-466, PHOSPHORYLATION AT
RP   SER-56, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Hepatoma;
RA   Bienvenut W.V., Fleming J., Leug H.Y.;
RL   Submitted (JAN-2010) to UniProtKB.
RN   [15]
RP   PROTEIN SEQUENCE OF 17-25 AND 55-70.
RC   TISSUE=Mammary carcinoma;
RX   PubMed=9150946; DOI=10.1002/elps.1150180342;
RA   Rasmussen R.K., Ji H., Eddes J.S., Moritz R.L., Reid G.E., Simpson R.J.,
RA   Dorow D.S.;
RT   "Two-dimensional electrophoretic analysis of human breast carcinoma
RT   proteins: mapping of proteins that bind to the SH3 domain of mixed lineage
RT   kinase MLK2.";
RL   Electrophoresis 18:588-598(1997).
RN   [16]
RP   PROTEIN SEQUENCE OF 51-64; 79-97; 105-113; 130-139; 146-155; 176-184;
RP   189-207; 223-235; 283-292; 295-304; 322-334; 346-373; 382-401 AND 411-439,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Vishwanath V., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [17]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 113-466, AND TISSUE SPECIFICITY.
RC   TISSUE=Fibroblast;
RX   PubMed=3371665; DOI=10.1016/0378-1119(88)90575-6;
RA   Perreau J., Lilienbaum A., Vasseur M., Paulin D.;
RT   "Nucleotide sequence of the human vimentin gene and regulation of its
RT   transcription in tissues and cultured cells.";
RL   Gene 62:7-16(1988).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 167-466.
RC   TISSUE=Osteosarcoma;
RX   PubMed=2323579; DOI=10.1016/0378-1119(90)90295-3;
RA   Gupta A.K., Aubin J.E., Waye M.M.Y.;
RT   "Isolation of a human vimentin cDNA with a long 3'-noncoding region from a
RT   human osteosarcoma cell line (MG-63).";
RL   Gene 86:303-304(1990).
RN   [19]
RP   PHOSPHORYLATION.
RX   PubMed=9175763; DOI=10.1006/bbrc.1997.6669;
RA   Matsuzawa K., Kosako H., Inagaki N., Shibata H., Mukai H., Ono Y.,
RA   Amano M., Kaibuchi K., Matsuura Y., Azuma I., Inagaki M.;
RT   "Domain-specific phosphorylation of vimentin and glial fibrillary acidic
RT   protein by PKN.";
RL   Biochem. Biophys. Res. Commun. 234:621-625(1997).
RN   [20]
RP   INTERACTION WITH PKP1 AND PKP2.
RX   PubMed=10852826; DOI=10.1242/jcs.113.13.2471;
RA   Hofmann I., Mertens C., Brettel M., Nimmrich V., Schnoelzer M.,
RA   Herrmann H.;
RT   "Interaction of plakophilins with desmoplakin and intermediate filament
RT   proteins: an in vitro analysis.";
RL   J. Cell Sci. 113:2471-2483(2000).
RN   [21]
RP   PHOSPHORYLATION AT SER-72.
RX   PubMed=12458200; DOI=10.1074/jbc.m210892200;
RA   Goto H., Yasui Y., Kawajiri A., Nigg E.A., Terada Y., Tatsuka M.,
RA   Nagata K., Inagaki M.;
RT   "Aurora-B regulates the cleavage furrow-specific vimentin phosphorylation
RT   in the cytokinetic process.";
RL   J. Biol. Chem. 278:8526-8530(2003).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT   "Proteomic characterization of the human centrosome by protein correlation
RT   profiling.";
RL   Nature 426:570-574(2003).
RN   [23]
RP   PHOSPHORYLATION AT SER-5; SER-7; SER-8; SER-9; SER-10; SER-39; SER-42;
RP   SER-72; SER-73; SER-420; SER-430; THR-458 AND SER-459, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY.
RX   PubMed=14762106; DOI=10.1242/jcs.00906;
RA   Eriksson J.E., He T., Trejo-Skalli A.V., Harmala-Brasken A.-S., Hellman J.,
RA   Chou Y.-H., Goldman R.D.;
RT   "Specific in vivo phosphorylation sites determine the assembly dynamics of
RT   vimentin intermediate filaments.";
RL   J. Cell Sci. 117:919-932(2004).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-117, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [25]
RP   INTERACTION WITH HCV CORE PROTEIN (MICROBIAL INFECTION).
RX   PubMed=15846844; DOI=10.1002/pmic.200401093;
RA   Kang S.-M., Shin M.-J., Kim J.-H., Oh J.-W.;
RT   "Proteomic profiling of cellular proteins interacting with the hepatitis C
RT   virus core protein.";
RL   Proteomics 5:2227-2237(2005).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-214 AND SER-412, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [27]
RP   INTERACTION WITH EPPK1.
RX   PubMed=16923132; DOI=10.1111/j.1346-8138.2006.00127.x;
RA   Wang W., Sumiyoshi H., Yoshioka H., Fujiwara S.;
RT   "Interactions between epiplakin and intermediate filaments.";
RL   J. Dermatol. 33:518-527(2006).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-56, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [29]
RP   INTERACTION WITH TOR1A AND TOR1AIP1.
RX   PubMed=16361107; DOI=10.1016/j.nbd.2005.10.012;
RA   Hewett J.W., Zeng J., Niland B.P., Bragg D.C., Breakefield X.O.;
RT   "Dystonia-causing mutant torsinA inhibits cell adhesion and neurite
RT   extension through interference with cytoskeletal dynamics.";
RL   Neurobiol. Dis. 22:98-111(2006).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-412, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17924679; DOI=10.1021/pr070152u;
RA   Yu L.R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.;
RT   "Improved titanium dioxide enrichment of phosphopeptides from HeLa cells
RT   and high confident phosphopeptide identification by cross-validation of
RT   MS/MS and MS/MS/MS spectra.";
RL   J. Proteome Res. 6:4150-4162(2007).
RN   [31]
RP   INTERACTION WITH BCAS3.
RX   PubMed=17505058; DOI=10.1210/me.2006-0514;
RA   Gururaj A.E., Peng S., Vadlamudi R.K., Kumar R.;
RT   "Estrogen induces expression of BCAS3, a novel estrogen receptor-alpha
RT   coactivator, through proline-, glutamic acid-, and leucine-rich protein-1
RT   (PELP1).";
RL   Mol. Endocrinol. 21:1847-1860(2007).
RN   [32]
RP   INTERACTION WITH STK33, AND PHOSPHORYLATION BY STK33.
RX   PubMed=18811945; DOI=10.1186/1471-2091-9-25;
RA   Brauksiepe B., Mujica A.O., Herrmann H., Schmidt E.R.;
RT   "The serine/threonine kinase Stk33 exhibits autophosphorylation and
RT   phosphorylates the intermediate filament protein Vimentin.";
RL   BMC Biochem. 9:25-25(2008).
RN   [33]
RP   INTERACTION WITH PRKCE, AND SUBCELLULAR LOCATION.
RX   PubMed=18408015; DOI=10.1074/jbc.m710436200;
RA   Sunesson L., Hellman U., Larsson C.;
RT   "Protein kinase Cepsilon binds peripherin and induces its aggregation,
RT   which is accompanied by apoptosis of neuroblastoma cells.";
RL   J. Biol. Chem. 283:16653-16664(2008).
RN   [34]
RP   INTERACTION WITH TOR1A.
RX   PubMed=18827015; DOI=10.1242/jcs.029454;
RA   Nery F.C., Zeng J., Niland B.P., Hewett J., Farley J., Irimia D., Li Y.,
RA   Wiche G., Sonnenberg A., Breakefield X.O.;
RT   "TorsinA binds the KASH domain of nesprins and participates in linkage
RT   between nuclear envelope and cytoskeleton.";
RL   J. Cell Sci. 121:3476-3486(2008).
RN   [35]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-412, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-5; SER-25; SER-34; SER-39;
RP   SER-42; SER-51; SER-56; TYR-61; SER-72; SER-73; SER-83; SER-144; SER-409;
RP   SER-412 AND SER-459, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [39]
RP   RETRACTED PAPER.
RX   PubMed=19270731; DOI=10.1371/journal.pone.0004730;
RA   Ahmed B.A., Bukhari I.A., Jeffus B.C., Harney J.T., Thyparambil S., Ziu E.,
RA   Fraer M., Rusch N.J., Zimniak P., Lupashin V., Tang D., Kilic F.;
RT   "The cellular distribution of serotonin transporter is impeded on
RT   serotonin-altered vimentin network.";
RL   PLoS ONE 4:E4730-E4730(2009).
RN   [40]
RP   RETRACTION NOTICE OF PUBMED:19270731.
RX   PubMed=30707744; DOI=10.1371/journal.pone.0211966;
RA   Ahmed B.A., Bukhari I.A., Jeffus B.C., Harney J.T., Thyparambil S., Ziu E.,
RA   Fraer M., Rusch N.J., Zimniak P., Lupashin V., Tang D., Kilic F.;
RT   "Retraction: The Cellular Distribution of Serotonin Transporter Is Impeded
RT   on Serotonin-Altered Vimentin Network.";
RL   PLoS ONE 14:e0211966-e0211966(2019).
RN   [41]
RP   INTERACTION WITH SCRIB, AND SUBCELLULAR LOCATION.
RX   PubMed=19386766; DOI=10.1091/mbc.e08-02-0199;
RA   Phua D.C., Humbert P.O., Hunziker W.;
RT   "Vimentin regulates scribble activity by protecting it from proteasomal
RT   degradation.";
RL   Mol. Biol. Cell 20:2841-2855(2009).
RN   [42]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-51; SER-56 AND TYR-61, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [43]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-120; LYS-139; LYS-373 AND
RP   LYS-445, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [44]
RP   GLYCOSYLATION AT SER-7; THR-33 AND SER-34.
RX   PubMed=20068230; DOI=10.1126/scisignal.2000526;
RA   Wang Z., Udeshi N.D., Slawson C., Compton P.D., Sakabe K., Cheung W.D.,
RA   Shabanowitz J., Hunt D.F., Hart G.W.;
RT   "Extensive crosstalk between O-GlcNAcylation and phosphorylation regulates
RT   cytokinesis.";
RL   Sci. Signal. 3:RA2-RA2(2010).
RN   [45]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-20; SER-42; SER-47; SER-51;
RP   SER-56; SER-73; SER-83; SER-144; SER-214; SER-226; SER-299; SER-412;
RP   SER-419; SER-420; THR-426; SER-430; THR-436 AND SER-459, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [46]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [47]
RP   FUNCTION IN COLLAGEN MRNA STABILIZATION, AND INTERACTION WITH LARP6.
RX   PubMed=21746880; DOI=10.1128/mcb.05263-11;
RA   Challa A.A., Stefanovic B.;
RT   "A novel role of vimentin filaments: binding and stabilization of collagen
RT   mRNAs.";
RL   Mol. Cell. Biol. 31:3773-3789(2011).
RN   [48]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-51; SER-144 AND SER-459, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [49]
RP   PHOSPHORYLATION AT SER-56, AND SUBCELLULAR LOCATION.
RX   PubMed=21465480; DOI=10.1002/jcp.22782;
RA   Lee K.Y., Liu L., Jin Y., Fu S.B., Rosales J.L.;
RT   "Cdk5 mediates vimentin Ser56 phosphorylation during GTP-induced secretion
RT   by neutrophils.";
RL   J. Cell. Physiol. 227:739-750(2012).
RN   [50]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S., Fischer-Posovszky P.,
RA   Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [51]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [52]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-25; SER-26; SER-39; SER-42;
RP   SER-47; SER-49; SER-51; SER-56; TYR-61; SER-66; SER-73; SER-214; SER-226;
RP   SER-299; SER-419; SER-420; SER-430; THR-436; SER-438; THR-446 AND SER-459,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [53]
RP   INTERACTION WITH DIAPH1, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=23325789; DOI=10.1091/mbc.e12-08-0597;
RA   Li D., Dammer E.B., Lucki N.C., Sewer M.B.;
RT   "cAMP-stimulated phosphorylation of diaphanous 1 regulates protein
RT   stability and interaction with binding partners in adrenocortical cells.";
RL   Mol. Biol. Cell 24:848-857(2013).
RN   [54]
RP   S-NITROSYLATION, AND DOMAIN.
RX   PubMed=25417112; DOI=10.1016/j.cell.2014.09.032;
RA   Jia J., Arif A., Terenzi F., Willard B., Plow E.F., Hazen S.L., Fox P.L.;
RT   "Target-selective protein S-nitrosylation by sequence motif recognition.";
RL   Cell 159:623-634(2014).
RN   [55]
RP   INTERACTION WITH PLEC.
RX   PubMed=24940650; DOI=10.1038/jid.2014.255;
RA   Bouameur J.E., Favre B., Fontao L., Lingasamy P., Begre N., Borradori L.;
RT   "Interaction of plectin with keratins 5 and 14: dependence on several
RT   plectin domains and keratin quaternary structure.";
RL   J. Invest. Dermatol. 134:2776-2783(2014).
RN   [56]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-20; SER-25; SER-39; SER-83;
RP   SER-87; SER-214; SER-419; THR-426 AND SER-430, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [57]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-445, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [58]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [59]
RP   INTERACTION WITH HDGF.
RX   PubMed=26845719; DOI=10.1515/hsz-2015-0273;
RA   Nuesse J., Mirastschijski U., Waespy M., Oetjen J., Brandes N., Rebello O.,
RA   Paroni F., Kelm S., Dietz F.;
RT   "Two new isoforms of the human hepatoma-derived growth factor interact with
RT   components of the cytoskeleton.";
RL   Biol. Chem. 397:417-436(2016).
RN   [60]
RP   INVOLVEMENT IN CTRCT30.
RX   PubMed=26694549; DOI=10.1002/humu.22948;
RA   Ma A.S., Grigg J.R., Ho G., Prokudin I., Farnsworth E., Holman K.,
RA   Cheng A., Billson F.A., Martin F., Fraser C., Mowat D., Smith J.,
RA   Christodoulou J., Flaherty M., Bennetts B., Jamieson R.V.;
RT   "Sporadic and familial congenital cataracts: mutational spectrum and new
RT   diagnoses using next-generation sequencing.";
RL   Hum. Mutat. 37:371-384(2016).
RN   [61]
RP   INTERACTION WITH NOD2, AND INDUCTION.
RX   PubMed=27812135; DOI=10.1371/journal.pone.0165420;
RA   Thiebaut R., Esmiol S., Lecine P., Mahfouz B., Hermant A., Nicoletti C.,
RA   Parnis S., Perroy J., Borg J.P., Pascoe L., Hugot J.P., Ollendorff V.;
RT   "Characterization and Genetic Analyses of New Genes Coding for NOD2
RT   Interacting Proteins.";
RL   PLoS ONE 11:E0165420-E0165420(2016).
RN   [62]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-104; LYS-120; LYS-129; LYS-139;
RP   LYS-223; LYS-262; LYS-294; LYS-313; LYS-373; LYS-439 AND LYS-445, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [63]
RP   INTERACTION WITH SRMS, SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=29496907; DOI=10.1074/mcp.ra118.000643;
RA   Goel R.K., Paczkowska M., Reimand J., Napper S., Lukong K.E.;
RT   "Phosphoproteomics analysis identifies novel candidate substrates of the
RT   non-receptor tyrosine kinase, SRMS.";
RL   Mol. Cell. Proteomics 17:925-947(2018).
RN   [64]
RP   INTERACTION WITH CHANDIPURA VIRUS GLYCOPROTEIN (MICROBIAL INFECTION).
RX   PubMed=32418904; DOI=10.1016/j.virusres.2020.198014;
RA   Kavathekar V.K., Dhanavade M.J., Sonawane K.D., Balakrishnan A.;
RT   "Role of cell surface vimentin in Chandipura virus replication in Neuro-2a
RT   cells.";
RL   Virus Res. 285:198014-198014(2020).
RN   [65]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 102-138.
RX   PubMed=11243787; DOI=10.1006/jmbi.2001.4442;
RA   Strelkov S.V., Herrmann H., Geisler N., Lustig A., Ivaninskii S.,
RA   Zimbelmann R., Burkhard P., Aebi U.;
RT   "Divide-and-conquer crystallographic approach towards an atomic structure
RT   of intermediate filaments.";
RL   J. Mol. Biol. 306:773-781(2001).
RN   [66]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 103-139 AND 328-411.
RX   PubMed=11889032; DOI=10.1093/emboj/21.6.1255;
RA   Strelkov S.V., Herrmann H., Geisler N., Wedig T., Zimbelmann R., Aebi U.,
RA   Burkhard P.;
RT   "Conserved segments 1A and 2B of the intermediate filament dimer: their
RT   atomic structures and role in filament assembly.";
RL   EMBO J. 21:1255-1266(2002).
RN   [67]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 263-334, COILED-COIL DOMAINS, AND
RP   SUBUNIT.
RX   PubMed=20176112; DOI=10.1016/j.jsb.2010.02.012;
RA   Nicolet S., Herrmann H., Aebi U., Strelkov S.V.;
RT   "Atomic structure of vimentin coil 2.";
RL   J. Struct. Biol. 170:369-376(2010).
RN   [68]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 261-335 OF MUTANT CYS-265.
RX   PubMed=22119849; DOI=10.1016/j.jsb.2011.11.014;
RA   Chernyatina A.A., Strelkov S.V.;
RT   "Stabilization of vimentin coil2 fragment via an engineered disulfide.";
RL   J. Struct. Biol. 177:46-53(2012).
RN   [69]
RP   VARIANT CTRCT30 LYS-151, AND CHARACTERIZATION OF VARIANT CTRCT30 LYS-151.
RX   PubMed=19126778; DOI=10.1093/hmg/ddn440;
RA   Muller M., Bhattacharya S.S., Moore T., Prescott Q., Wedig T., Herrmann H.,
RA   Magin T.M.;
RT   "Dominant cataract formation in association with a vimentin assembly
RT   disrupting mutation.";
RL   Hum. Mol. Genet. 18:1052-1057(2009).
RN   [70]
RP   VARIANT CTRCT30 ARG-208.
RX   PubMed=28450710; DOI=10.1038/s41598-017-01182-9;
RA   Zhai Y., Li J., Yu W., Zhu S., Yu Y., Wu M., Sun G., Gong X., Yao K.;
RT   "Targeted exome sequencing of congenital cataracts related genes:
RT   broadening the mutation spectrum and genotype-phenotype correlations in 27
RT   Chinese Han families.";
RL   Sci. Rep. 7:1219-1219(2017).
CC   -!- FUNCTION: Vimentins are class-III intermediate filaments found in
CC       various non-epithelial cells, especially mesenchymal cells. Vimentin is
CC       attached to the nucleus, endoplasmic reticulum, and mitochondria,
CC       either laterally or terminally. Plays a role in cell directional
CC       movement, orientation, cell sheet organization and Golgi complex
CC       polarization at the cell migration front (By similarity). Protects
CC       SCRIB from proteasomal degradation and facilitates its localization to
CC       intermediate filaments in a cell contact-mediated manner (By
CC       similarity). May promote axon outgrowth and motor fiber repair via DSP-
CC       mediated recruitment to outgrowth tips (By similarity).
CC       {ECO:0000250|UniProtKB:A0A8C0N8E3, ECO:0000250|UniProtKB:P20152,
CC       ECO:0000250|UniProtKB:P31000}.
CC   -!- FUNCTION: Involved with LARP6 in the stabilization of type I collagen
CC       mRNAs for CO1A1 and CO1A2. {ECO:0000269|PubMed:21746880}.
CC   -!- SUBUNIT: Homomer assembled from elementary dimers (PubMed:20176112).
CC       Identified in complexes that contain VIM, EZR, AHNAK, BFSP1, BFSP2,
CC       ANK2, PLEC, PRX and spectrin (By similarity). Identified in a complex
CC       containing at least DSP, JUP, VIM and CDH2; the complex is more
CC       abundant following crush injury in regenerating motor neurons and may
CC       promote axon outgrowth and motor fiber repair (By similarity).
CC       Interacts with BCAS3 (PubMed:17505058). Interacts with LGSN (By
CC       similarity). Interacts with SYNM (By similarity). Interacts (via rod
CC       region) with PLEC (via CH 1 domain) (By similarity). Interacts with
CC       PLEC isoform 1C (PubMed:24940650). Interacts with STK33
CC       (PubMed:18811945). Interacts with LARP6 (PubMed:21746880). Interacts
CC       with RAB8B (By similarity). Interacts with TOR1A; the interaction
CC       associates TOR1A with the cytoskeleton (PubMed:16361107,
CC       PubMed:18827015). Interacts with TOR1AIP1 (PubMed:16361107). Interacts
CC       with DIAPH1 (PubMed:23325789). Interacts with EPPK1; interaction is
CC       dependent of higher-order structure of intermediate filament
CC       (PubMed:16923132). Interacts with the non-receptor tyrosine kinase
CC       SRMS; the interaction leads to phosphorylation of VIM
CC       (PubMed:29496907). Interacts with NOD2 (PubMed:27812135). Interacts
CC       (via head region) with CORO1C (By similarity). Interacts with HDGF
CC       (isoform 2) (PubMed:26845719). Interacts with PRKCE (via phorbol-
CC       ester/DAG-type 2 domain) (PubMed:18408015). Interacts with BFSP2 (By
CC       similarity). Interacts with PPL (By similarity). Interacts (via rod
CC       domain) with PKP1 (PubMed:10852826). Interacts with PKP2
CC       (PubMed:10852826). Interacts with SCRIB (via PDZ domains); the
CC       interaction protects SCRIB from proteasomal degradation and facilitates
CC       SCRIB localization to intermediate filaments, the interaction is
CC       reduced by cell contact inhibition (PubMed:19386766).
CC       {ECO:0000250|UniProtKB:P20152, ECO:0000250|UniProtKB:P31000,
CC       ECO:0000269|PubMed:10852826, ECO:0000269|PubMed:16361107,
CC       ECO:0000269|PubMed:16923132, ECO:0000269|PubMed:17505058,
CC       ECO:0000269|PubMed:18408015, ECO:0000269|PubMed:18811945,
CC       ECO:0000269|PubMed:18827015, ECO:0000269|PubMed:19386766,
CC       ECO:0000269|PubMed:20176112, ECO:0000269|PubMed:21746880,
CC       ECO:0000269|PubMed:23325789, ECO:0000269|PubMed:24940650,
CC       ECO:0000269|PubMed:26845719, ECO:0000269|PubMed:27812135,
CC       ECO:0000269|PubMed:29496907}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HCV core protein.
CC       {ECO:0000269|PubMed:15846844}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Chandipura virus
CC       glycoprotein; this interaction might facilitate the binding of the
CC       virus to the cells. {ECO:0000269|PubMed:32418904}.
CC   -!- INTERACTION:
CC       P08670; Q9BYF1: ACE2; NbExp=4; IntAct=EBI-353844, EBI-7730807;
CC       P08670; Q6DHV7-2: ADAL; NbExp=3; IntAct=EBI-353844, EBI-18899653;
CC       P08670; Q8N302-2: AGGF1; NbExp=3; IntAct=EBI-353844, EBI-25838028;
CC       P08670; P54819: AK2; NbExp=3; IntAct=EBI-353844, EBI-1056291;
CC       P08670; P31749: AKT1; NbExp=29; IntAct=EBI-353844, EBI-296087;
CC       P08670; P31751: AKT2; NbExp=6; IntAct=EBI-353844, EBI-296058;
CC       P08670; Q9H6L4: ARMC7; NbExp=3; IntAct=EBI-353844, EBI-742909;
CC       P08670; Q6XD76: ASCL4; NbExp=3; IntAct=EBI-353844, EBI-10254793;
CC       P08670; Q9UBB4: ATXN10; NbExp=3; IntAct=EBI-353844, EBI-702390;
CC       P08670; Q9H6U6: BCAS3; NbExp=3; IntAct=EBI-353844, EBI-6083685;
CC       P08670; Q14457: BECN1; NbExp=3; IntAct=EBI-353844, EBI-949378;
CC       P08670; P51451: BLK; NbExp=3; IntAct=EBI-353844, EBI-2105445;
CC       P08670; Q13895: BYSL; NbExp=3; IntAct=EBI-353844, EBI-358049;
CC       P08670; Q8TAB5: C1orf216; NbExp=3; IntAct=EBI-353844, EBI-747505;
CC       P08670; Q9UQM7: CAMK2A; NbExp=3; IntAct=EBI-353844, EBI-1383687;
CC       P08670; Q9HC52: CBX8; NbExp=3; IntAct=EBI-353844, EBI-712912;
CC       P08670; Q96HB5: CCDC120; NbExp=3; IntAct=EBI-353844, EBI-744556;
CC       P08670; Q9Y3D0: CIAO2B; NbExp=3; IntAct=EBI-353844, EBI-744045;
CC       P08670; Q14194: CRMP1; NbExp=3; IntAct=EBI-353844, EBI-473101;
CC       P08670; Q8WUE5: CT55; NbExp=3; IntAct=EBI-353844, EBI-6873363;
CC       P08670; Q2TBE0: CWF19L2; NbExp=3; IntAct=EBI-353844, EBI-5453285;
CC       P08670; P17661: DES; NbExp=8; IntAct=EBI-353844, EBI-1055572;
CC       P08670; O77932: DXO; NbExp=3; IntAct=EBI-353844, EBI-372173;
CC       P08670; Q6NXG1: ESRP1; NbExp=3; IntAct=EBI-353844, EBI-10213520;
CC       P08670; Q3B820: FAM161A; NbExp=3; IntAct=EBI-353844, EBI-719941;
CC       P08670; Q96GL9: FAM163A; NbExp=3; IntAct=EBI-353844, EBI-11793142;
CC       P08670; O15287: FANCG; NbExp=3; IntAct=EBI-353844, EBI-81610;
CC       P08670; P55040: GEM; NbExp=3; IntAct=EBI-353844, EBI-744104;
CC       P08670; P14136: GFAP; NbExp=10; IntAct=EBI-353844, EBI-744302;
CC       P08670; Q4G1C9-2: GLIPR1L2; NbExp=3; IntAct=EBI-353844, EBI-20835942;
CC       P08670; Q96LI6: HSFY2; NbExp=3; IntAct=EBI-353844, EBI-3957665;
CC       P08670; P11021: HSPA5; NbExp=3; IntAct=EBI-353844, EBI-354921;
CC       P08670; P83110-1: HTRA3; NbExp=4; IntAct=EBI-353844, EBI-25469082;
CC       P08670; P83110-2: HTRA3; NbExp=5; IntAct=EBI-353844, EBI-22017714;
CC       P08670; P42858: HTT; NbExp=4; IntAct=EBI-353844, EBI-466029;
CC       P08670; Q0VD86: INCA1; NbExp=3; IntAct=EBI-353844, EBI-6509505;
CC       P08670; Q92551: IP6K1; NbExp=3; IntAct=EBI-353844, EBI-751911;
CC       P08670; O95251: KAT7; NbExp=4; IntAct=EBI-353844, EBI-473199;
CC       P08670; Q6ZU52: KIAA0408; NbExp=4; IntAct=EBI-353844, EBI-739493;
CC       P08670; Q9HAQ2: KIF9; NbExp=3; IntAct=EBI-353844, EBI-8472129;
CC       P08670; Q9BVG8-5: KIFC3; NbExp=3; IntAct=EBI-353844, EBI-14069005;
CC       P08670; O14901: KLF11; NbExp=3; IntAct=EBI-353844, EBI-948266;
CC       P08670; P35900: KRT20; NbExp=8; IntAct=EBI-353844, EBI-742094;
CC       P08670; O95678: KRT75; NbExp=3; IntAct=EBI-353844, EBI-2949715;
CC       P08670; P05787: KRT8; NbExp=2; IntAct=EBI-353844, EBI-297852;
CC       P08670; Q6IAA8: LAMTOR1; NbExp=3; IntAct=EBI-353844, EBI-715385;
CC       P08670; Q14847-2: LASP1; NbExp=3; IntAct=EBI-353844, EBI-9088686;
CC       P08670; Q8TCE9: LGALS14; NbExp=3; IntAct=EBI-353844, EBI-10274069;
CC       P08670; Q6ZQX7-4: LIAT1; NbExp=3; IntAct=EBI-353844, EBI-25830459;
CC       P08670; Q9Y4K0: LOXL2; NbExp=6; IntAct=EBI-353844, EBI-7172227;
CC       P08670; Q9NS73-5: MBIP; NbExp=3; IntAct=EBI-353844, EBI-10182361;
CC       P08670; Q8IVT4: MGC50722; NbExp=3; IntAct=EBI-353844, EBI-14086479;
CC       P08670; O76036: NCR1; NbExp=3; IntAct=EBI-353844, EBI-13915737;
CC       P08670; I6L9F6: NEFL; NbExp=3; IntAct=EBI-353844, EBI-10178578;
CC       P08670; P07196: NEFL; NbExp=6; IntAct=EBI-353844, EBI-475646;
CC       P08670; P07197: NEFM; NbExp=10; IntAct=EBI-353844, EBI-1105035;
CC       P08670; P48681: NES; NbExp=5; IntAct=EBI-353844, EBI-10966836;
CC       P08670; Q8NI38: NFKBID; NbExp=3; IntAct=EBI-353844, EBI-10271199;
CC       P08670; Q9HC29: NOD2; NbExp=12; IntAct=EBI-353844, EBI-7445625;
CC       P08670; Q96IZ0: PAWR; NbExp=2; IntAct=EBI-353844, EBI-595869;
CC       P08670; Q16512: PKN1; NbExp=3; IntAct=EBI-353844, EBI-602382;
CC       P08670; Q13835-2: PKP1; NbExp=3; IntAct=EBI-353844, EBI-9087684;
CC       P08670; Q96PV4: PNMA5; NbExp=6; IntAct=EBI-353844, EBI-10171633;
CC       P08670; O60437: PPL; NbExp=3; IntAct=EBI-353844, EBI-368321;
CC       P08670; Q6NYC8: PPP1R18; NbExp=3; IntAct=EBI-353844, EBI-2557469;
CC       P08670; P41219: PRPH; NbExp=4; IntAct=EBI-353844, EBI-752074;
CC       P08670; Q8WUY3: PRUNE2; NbExp=3; IntAct=EBI-353844, EBI-743880;
CC       P08670; P54727: RAD23B; NbExp=2; IntAct=EBI-353844, EBI-954531;
CC       P08670; Q9UJD0: RIMS3; NbExp=3; IntAct=EBI-353844, EBI-3909436;
CC       P08670; Q9BWG6: SCNM1; NbExp=3; IntAct=EBI-353844, EBI-748391;
CC       P08670; P12757: SKIL; NbExp=3; IntAct=EBI-353844, EBI-2902468;
CC       P08670; Q12824: SMARCB1; NbExp=4; IntAct=EBI-353844, EBI-358419;
CC       P08670; Q7Z614-3: SNX20; NbExp=3; IntAct=EBI-353844, EBI-12336127;
CC       P08670; Q96BD6: SPSB1; NbExp=3; IntAct=EBI-353844, EBI-2659201;
CC       P08670; Q99619: SPSB2; NbExp=3; IntAct=EBI-353844, EBI-2323209;
CC       P08670; Q9H7C4: SYNC; NbExp=7; IntAct=EBI-353844, EBI-11285923;
CC       P08670; O60506-4: SYNCRIP; NbExp=3; IntAct=EBI-353844, EBI-11123832;
CC       P08670; O15273: TCAP; NbExp=3; IntAct=EBI-353844, EBI-954089;
CC       P08670; Q15560: TCEA2; NbExp=3; IntAct=EBI-353844, EBI-710310;
CC       P08670; P15923-3: TCF3; NbExp=3; IntAct=EBI-353844, EBI-12000326;
CC       P08670; Q13428-5: TCOF1; NbExp=3; IntAct=EBI-353844, EBI-25832010;
CC       P08670; Q5T1C6: THEM4; NbExp=3; IntAct=EBI-353844, EBI-7684443;
CC       P08670; Q08117-2: TLE5; NbExp=3; IntAct=EBI-353844, EBI-11741437;
CC       P08670; Q7Z403: TMC6; NbExp=3; IntAct=EBI-353844, EBI-9088037;
CC       P08670; Q12888: TP53BP1; NbExp=3; IntAct=EBI-353844, EBI-396540;
CC       P08670; Q14142: TRIM14; NbExp=3; IntAct=EBI-353844, EBI-2820256;
CC       P08670; O95361: TRIM16; NbExp=3; IntAct=EBI-353844, EBI-727384;
CC       P08670; Q9BQE3: TUBA1C; NbExp=3; IntAct=EBI-353844, EBI-1103245;
CC       P08670; Q5VYS8-5: TUT7; NbExp=3; IntAct=EBI-353844, EBI-9088812;
CC       P08670; Q8N3L3: TXLNB; NbExp=6; IntAct=EBI-353844, EBI-6116822;
CC       P08670; Q08AM6: VAC14; NbExp=3; IntAct=EBI-353844, EBI-2107455;
CC       P08670; P08670: VIM; NbExp=11; IntAct=EBI-353844, EBI-353844;
CC       P08670; Q9H270: VPS11; NbExp=3; IntAct=EBI-353844, EBI-373380;
CC       P08670; B7ZLI8: WHR1; NbExp=3; IntAct=EBI-353844, EBI-10176124;
CC       P08670; Q9NQH7: XPNPEP3; NbExp=3; IntAct=EBI-353844, EBI-1171467;
CC       P08670; P61981: YWHAG; NbExp=3; IntAct=EBI-353844, EBI-359832;
CC       P08670; P63104: YWHAZ; NbExp=3; IntAct=EBI-353844, EBI-347088;
CC       P08670; P26651: ZFP36; NbExp=3; IntAct=EBI-353844, EBI-374248;
CC       P08670; P17024: ZNF20; NbExp=3; IntAct=EBI-353844, EBI-717634;
CC       P08670; Q7Z3I7: ZNF572; NbExp=3; IntAct=EBI-353844, EBI-10172590;
CC       P08670; Q925J2: Pkd1; Xeno; NbExp=2; IntAct=EBI-353844, EBI-7985677;
CC       P08670; PRO_0000449633 [P0DTD1]: rep; Xeno; NbExp=4; IntAct=EBI-353844, EBI-25492395;
CC       P08670; P0DTC2: S; Xeno; NbExp=4; IntAct=EBI-353844, EBI-25474821;
CC       P08670; PRO_0000037966 [P14340]; Xeno; NbExp=10; IntAct=EBI-353844, EBI-9844509;
CC       P08670; PRO_0000037566 [P27958]; Xeno; NbExp=4; IntAct=EBI-353844, EBI-6377335;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:19386766,
CC       ECO:0000269|PubMed:21465480, ECO:0000269|PubMed:29496907}. Cytoplasm,
CC       cytoskeleton {ECO:0000269|PubMed:18408015,
CC       ECO:0000269|PubMed:29496907}. Nucleus matrix
CC       {ECO:0000250|UniProtKB:P31000}. Cell membrane
CC       {ECO:0000250|UniProtKB:P20152}. Cell projection, axon
CC       {ECO:0000250|UniProtKB:P20152}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in fibroblasts, some expression in
CC       T- and B-lymphocytes, and little or no expression in Burkitt's lymphoma
CC       cell lines. Expressed in many hormone-independent mammary carcinoma
CC       cell lines. {ECO:0000269|PubMed:2472876, ECO:0000269|PubMed:3371665}.
CC   -!- INDUCTION: Up-regulated by muramyl-dipeptide and lipopolysaccharide.
CC       {ECO:0000269|PubMed:27812135}.
CC   -!- DOMAIN: The central alpha-helical coiled-coil IF rod domain mediates
CC       elementary homodimerization. {ECO:0000269|PubMed:20176112}.
CC   -!- DOMAIN: The [IL]-x-C-x-x-[DE] motif is a proposed target motif for
CC       cysteine S-nitrosylation mediated by the iNOS-S100A8/A9
CC       transnitrosylase complex. {ECO:0000305|PubMed:25417112}.
CC   -!- PTM: Filament disassembly during mitosis is promoted by phosphorylation
CC       at Ser-55 as well as by nestin (By similarity). One of the most
CC       prominent phosphoproteins in various cells of mesenchymal origin.
CC       Phosphorylation is enhanced during cell division, at which time
CC       vimentin filaments are significantly reorganized. Phosphorylation by
CC       PKN1 inhibits the formation of filaments. Phosphorylated at Ser-56 by
CC       CDK5 during neutrophil secretion in the cytoplasm (PubMed:21465480).
CC       Phosphorylated by STK33 (PubMed:18811945). Phosphorylated on tyrosine
CC       residues by SRMS (PubMed:29496907). {ECO:0000250|UniProtKB:P31000,
CC       ECO:0000269|PubMed:18811945, ECO:0000269|PubMed:21465480,
CC       ECO:0000269|PubMed:29496907, ECO:0000269|Ref.14}.
CC   -!- PTM: O-glycosylated during cytokinesis at sites identical or close to
CC       phosphorylation sites, this interferes with the phosphorylation status.
CC       {ECO:0000269|PubMed:20068230}.
CC   -!- PTM: S-nitrosylation is induced by interferon-gamma and oxidatively-
CC       modified low-densitity lipoprotein (LDL(ox)) possibly implicating the
CC       iNOS-S100A8/9 transnitrosylase complex. {ECO:0000305|PubMed:25417112}.
CC   -!- DISEASE: Cataract 30, multiple types (CTRCT30) [MIM:116300]: An
CC       opacification of the crystalline lens of the eye that frequently
CC       results in visual impairment or blindness. Opacities vary in
CC       morphology, are often confined to a portion of the lens, and may be
CC       static or progressive. In general, the more posteriorly located and
CC       dense an opacity, the greater the impact on visual function.
CC       {ECO:0000269|PubMed:19126778, ECO:0000269|PubMed:26694549,
CC       ECO:0000269|PubMed:28450710}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the intermediate filament family.
CC       {ECO:0000255|PROSITE-ProRule:PRU01188}.
CC   -!- CAUTION: Was reported to interact with SLC6A4, however the paper was
CC       retracted as some results and conclusions are not reliable.
CC       {ECO:0000269|PubMed:19270731, ECO:0000305|PubMed:30707744}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB71275.1; Type=Miscellaneous discrepancy; Note=Product of a cloning artifact.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Vimentin entry;
CC       URL="https://en.wikipedia.org/wiki/Vimentin";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M14144; AAA61279.1; -; Genomic_DNA.
DR   EMBL; X56134; CAA39600.1; -; mRNA.
DR   EMBL; AF328728; AAN09720.1; -; mRNA.
DR   EMBL; Z19554; CAA79613.2; -; mRNA.
DR   EMBL; AK056766; BAB71275.1; ALT_SEQ; mRNA.
DR   EMBL; AK097336; BAC05002.1; -; mRNA.
DR   EMBL; AK290643; BAF83332.1; -; mRNA.
DR   EMBL; CR407690; CAG28618.1; -; mRNA.
DR   EMBL; AK222507; BAD96227.1; -; mRNA.
DR   EMBL; AK222602; BAD96322.1; -; mRNA.
DR   EMBL; EF445046; ACA06101.1; -; Genomic_DNA.
DR   EMBL; EF445046; ACA06102.1; -; Genomic_DNA.
DR   EMBL; AL133415; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471072; EAW86215.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW86216.1; -; Genomic_DNA.
DR   EMBL; BC000163; AAH00163.2; -; mRNA.
DR   EMBL; BC030573; AAH30573.1; -; mRNA.
DR   EMBL; BC066956; AAH66956.1; -; mRNA.
DR   EMBL; X16478; CAA34499.1; -; mRNA.
DR   EMBL; M18895; AAA61281.2; -; Genomic_DNA.
DR   EMBL; M18888; AAA61281.2; JOINED; Genomic_DNA.
DR   EMBL; M18889; AAA61281.2; JOINED; Genomic_DNA.
DR   EMBL; M18890; AAA61281.2; JOINED; Genomic_DNA.
DR   EMBL; M18891; AAA61281.2; JOINED; Genomic_DNA.
DR   EMBL; M18892; AAA61281.2; JOINED; Genomic_DNA.
DR   EMBL; M18893; AAA61281.2; JOINED; Genomic_DNA.
DR   EMBL; M18894; AAA61281.2; JOINED; Genomic_DNA.
DR   EMBL; M25246; AAA61282.1; -; mRNA.
DR   CCDS; CCDS7120.1; -.
DR   PIR; S13115; A25074.
DR   RefSeq; NP_003371.2; NM_003380.5.
DR   PDB; 1GK4; X-ray; 2.30 A; A/B/C/D/E/F=328-411.
DR   PDB; 1GK6; X-ray; 1.90 A; A/B=385-412.
DR   PDB; 1GK7; X-ray; 1.40 A; A=102-138.
DR   PDB; 3G1E; X-ray; 1.83 A; A/B=102-138.
DR   PDB; 3KLT; X-ray; 2.70 A; A/B/C/D=263-334.
DR   PDB; 3S4R; X-ray; 2.45 A; A/B=99-189.
DR   PDB; 3SSU; X-ray; 2.60 A; A/B=99-189.
DR   PDB; 3SWK; X-ray; 1.70 A; A/B=153-238.
DR   PDB; 3TRT; X-ray; 2.30 A; A/B=261-335.
DR   PDB; 3UF1; X-ray; 2.81 A; A/B/C/D=144-251.
DR   PDB; 4MCY; X-ray; 2.30 A; C=66-78.
DR   PDB; 4MCZ; X-ray; 2.41 A; C=59-71.
DR   PDB; 4MD0; X-ray; 2.19 A; C=59-71.
DR   PDB; 4MD5; X-ray; 1.65 A; C=66-78.
DR   PDB; 4MDI; X-ray; 2.00 A; C=66-78.
DR   PDB; 4MDJ; X-ray; 1.70 A; C=66-78.
DR   PDB; 4YPC; X-ray; 1.44 A; A=161-243.
DR   PDB; 4YV3; X-ray; 2.00 A; A/B/C=161-238.
DR   PDB; 5WHF; X-ray; 2.25 A; A/B/C/D/E/F/G/H=153-238.
DR   PDB; 6ATF; X-ray; 1.90 A; C/F=59-71.
DR   PDB; 6ATI; X-ray; 1.98 A; C/F=59-71.
DR   PDB; 6BIR; X-ray; 2.30 A; C=419-431.
DR   PDB; 6YXK; X-ray; 2.00 A; C=59-74.
DR   PDB; 8RVE; EM; 7.20 A; 0/1/2/3/4/5/6/7/8/9/A/AA/AB/AC/AD/AE/AF/AG/AH/AI/AJ/AK/AL/AM/AN/AO/AP/B/C/D=1-466.
DR   PDB; 8TRQ; X-ray; 2.75 A; C=59-71.
DR   PDB; 8TRR; X-ray; 2.65 A; C/H=59-71.
DR   PDBsum; 1GK4; -.
DR   PDBsum; 1GK6; -.
DR   PDBsum; 1GK7; -.
DR   PDBsum; 3G1E; -.
DR   PDBsum; 3KLT; -.
DR   PDBsum; 3S4R; -.
DR   PDBsum; 3SSU; -.
DR   PDBsum; 3SWK; -.
DR   PDBsum; 3TRT; -.
DR   PDBsum; 3UF1; -.
DR   PDBsum; 4MCY; -.
DR   PDBsum; 4MCZ; -.
DR   PDBsum; 4MD0; -.
DR   PDBsum; 4MD5; -.
DR   PDBsum; 4MDI; -.
DR   PDBsum; 4MDJ; -.
DR   PDBsum; 4YPC; -.
DR   PDBsum; 4YV3; -.
DR   PDBsum; 5WHF; -.
DR   PDBsum; 6ATF; -.
DR   PDBsum; 6ATI; -.
DR   PDBsum; 6BIR; -.
DR   PDBsum; 6YXK; -.
DR   PDBsum; 8RVE; -.
DR   PDBsum; 8TRQ; -.
DR   PDBsum; 8TRR; -.
DR   AlphaFoldDB; P08670; -.
DR   EMDB; EMD-19562; -.
DR   EMDB; EMD-19563; -.
DR   SMR; P08670; -.
DR   BioGRID; 113272; 845.
DR   CORUM; P08670; -.
DR   DIP; DIP-32507N; -.
DR   FunCoup; P08670; 815.
DR   IntAct; P08670; 419.
DR   MINT; P08670; -.
DR   STRING; 9606.ENSP00000446007; -.
DR   BindingDB; P08670; -.
DR   ChEMBL; CHEMBL3712854; -.
DR   DrugBank; DB11638; Artenimol.
DR   DrugBank; DB12695; Phenethyl Isothiocyanate.
DR   MoonDB; P08670; Predicted.
DR   TCDB; 9.B.392.4.5; the golgi apparatus golgin (golgin) family.
DR   CarbonylDB; P08670; -.
DR   GlyConnect; 2867; 1 O-GlcNAc glycan (3 sites).
DR   GlyCosmos; P08670; 17 sites, 2 glycans.
DR   GlyGen; P08670; 31 sites, 2 N-linked glycans (2 sites), 2 O-linked glycans (29 sites).
DR   iPTMnet; P08670; -.
DR   MetOSite; P08670; -.
DR   PhosphoSitePlus; P08670; -.
DR   SwissPalm; P08670; -.
DR   BioMuta; VIM; -.
DR   DMDM; 55977767; -.
DR   OGP; P08670; -.
DR   REPRODUCTION-2DPAGE; IPI00418471; -.
DR   REPRODUCTION-2DPAGE; P08670; -.
DR   CPTAC; CPTAC-1017; -.
DR   CPTAC; CPTAC-1018; -.
DR   CPTAC; CPTAC-1036; -.
DR   CPTAC; CPTAC-1303; -.
DR   CPTAC; CPTAC-297; -.
DR   CPTAC; CPTAC-298; -.
DR   jPOST; P08670; -.
DR   MassIVE; P08670; -.
DR   PaxDb; 9606-ENSP00000446007; -.
DR   PeptideAtlas; P08670; -.
DR   PRIDE; P08670; -.
DR   ProteomicsDB; 52153; -.
DR   Pumba; P08670; -.
DR   TopDownProteomics; P08670; -.
DR   ABCD; P08670; 18 sequenced antibodies.
DR   Antibodypedia; 938; 3755 antibodies from 62 providers.
DR   DNASU; 7431; -.
DR   Ensembl; ENST00000224237.9; ENSP00000224237.5; ENSG00000026025.17.
DR   Ensembl; ENST00000544301.7; ENSP00000446007.1; ENSG00000026025.17.
DR   GeneID; 7431; -.
DR   KEGG; hsa:7431; -.
DR   MANE-Select; ENST00000544301.7; ENSP00000446007.1; NM_003380.5; NP_003371.2.
DR   AGR; HGNC:12692; -.
DR   ClinPGx; PA37311; -.
DR   CTD; 7431; -.
DR   DisGeNET; 7431; -.
DR   GeneCards; VIM; -.
DR   HGNC; HGNC:12692; VIM.
DR   HPA; ENSG00000026025; Low tissue specificity.
DR   MalaCards; VIM; -.
DR   MIM; 116300; phenotype.
DR   MIM; 193060; gene.
DR   OpenTargets; ENSG00000026025; -.
DR   Orphanet; 675396; Epithelioid hemangioma.
DR   Orphanet; 98984; Pulverulent cataract.
DR   VEuPathDB; HostDB:ENSG00000026025; -.
DR   eggNOG; KOG0977; Eukaryota.
DR   GeneTree; ENSGT00940000156146; -.
DR   InParanoid; P08670; -.
DR   OMA; GGMYATK; -.
DR   OrthoDB; 2441647at2759; -.
DR   PAN-GO; P08670; 6 GO annotations based on evolutionary models.
DR   PhylomeDB; P08670; -.
DR   PathwayCommons; P08670; -.
DR   Reactome; R-HSA-264870; Caspase-mediated cleavage of cytoskeletal proteins.
DR   Reactome; R-HSA-390522; Striated Muscle Contraction.
DR   Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR   Reactome; R-HSA-9013422; RHOBTB1 GTPase cycle.
DR   Reactome; R-HSA-9613829; Chaperone Mediated Autophagy.
DR   Reactome; R-HSA-9615710; Late endosomal microautophagy.
DR   Reactome; R-HSA-9646399; Aggrephagy.
DR   Reactome; R-HSA-9927432; Developmental Lineage of Mammary Gland Myoepithelial Cells.
DR   SignaLink; P08670; -.
DR   SIGNOR; P08670; -.
DR   Agora; ENSG00000026025; Agora Nominated Target for Alzheimer's Disease.
DR   BioGRID-ORCS; 7431; 9 hits in 1163 CRISPR screens.
DR   CD-CODE; 91857CE7; Nucleolus.
DR   CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities.
DR   ChiTaRS; VIM; human.
DR   EvolutionaryTrace; P08670; -.
DR   GeneWiki; Vimentin; -.
DR   GenomeRNAi; 7431; -.
DR   Pharos; P08670; Tbio.
DR   PRO; PR:P08670; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; P08670; protein.
DR   Bgee; ENSG00000026025; Expressed in ventricular zone and 216 other cell types or tissues.
DR   ExpressionAtlas; P08670; baseline and differential.
DR   GO; GO:0030424; C:axon; IBA:GO_Central.
DR   GO; GO:0031252; C:cell leading edge; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; IDA:MGI.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0005882; C:intermediate filament; IDA:UniProtKB.
DR   GO; GO:0045111; C:intermediate filament cytoskeleton; IDA:HPA.
DR   GO; GO:0005815; C:microtubule organizing center; TAS:Reactome.
DR   GO; GO:0016363; C:nuclear matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005777; C:peroxisome; IDA:UniProtKB.
DR   GO; GO:0045335; C:phagocytic vesicle; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0003725; F:double-stranded RNA binding; IDA:MGI.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:1990254; F:keratin filament binding; IPI:AgBase.
DR   GO; GO:0060090; F:molecular adaptor activity; EXP:DisProt.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:UniProtKB.
DR   GO; GO:0097110; F:scaffold protein binding; IPI:BHF-UCL.
DR   GO; GO:0005200; F:structural constituent of cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0005212; F:structural constituent of eye lens; IEA:Ensembl.
DR   GO; GO:0014002; P:astrocyte development; IEA:Ensembl.
DR   GO; GO:0060020; P:Bergmann glial cell differentiation; IEA:Ensembl.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IMP:UniProtKB.
DR   GO; GO:0071225; P:cellular response to muramyl dipeptide; IMP:UniProtKB.
DR   GO; GO:0071346; P:cellular response to type II interferon; IEA:Ensembl.
DR   GO; GO:0045109; P:intermediate filament organization; ISS:UniProtKB.
DR   GO; GO:0070307; P:lens fiber cell development; IEA:Ensembl.
DR   GO; GO:0010977; P:negative regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:0031175; P:neuron projection development; IEA:Ensembl.
DR   GO; GO:0032967; P:positive regulation of collagen biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0043488; P:regulation of mRNA stability; IMP:UniProtKB.
DR   DisProt; DP02862; -.
DR   FunFam; 1.20.5.1160:FF:000001; Keratin type II; 1.
DR   FunFam; 1.20.5.170:FF:000002; Type I keratin KA11; 1.
DR   FunFam; 1.20.5.500:FF:000001; Type II keratin 23; 1.
DR   Gene3D; 1.20.5.170; -; 1.
DR   Gene3D; 1.20.5.500; Single helix bin; 1.
DR   Gene3D; 1.20.5.1160; Vasodilator-stimulated phosphoprotein; 1.
DR   InterPro; IPR018039; IF_conserved.
DR   InterPro; IPR039008; IF_rod_dom.
DR   InterPro; IPR006821; Intermed_filament_DNA-bd.
DR   InterPro; IPR050405; Intermediate_filament.
DR   PANTHER; PTHR45652; GLIAL FIBRILLARY ACIDIC PROTEIN; 1.
DR   PANTHER; PTHR45652:SF5; VIMENTIN; 1.
DR   Pfam; PF00038; Filament; 1.
DR   Pfam; PF04732; Filament_head; 1.
DR   SMART; SM01391; Filament; 1.
DR   SUPFAM; SSF64593; Intermediate filament protein, coiled coil region; 2.
DR   PROSITE; PS00226; IF_ROD_1; 1.
DR   PROSITE; PS51842; IF_ROD_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cataract; Cell membrane; Cell projection;
KW   Coiled coil; Cytoplasm; Cytoskeleton; Direct protein sequencing;
KW   Disease variant; Glycoprotein; Host-virus interaction;
KW   Intermediate filament; Isopeptide bond; Membrane; Nucleus; Phosphoprotein;
KW   Proteomics identification; Reference proteome; S-nitrosylation;
KW   Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|Ref.13"
FT   CHAIN           2..466
FT                   /note="Vimentin"
FT                   /id="PRO_0000063754"
FT   DOMAIN          103..411
FT                   /note="IF rod"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01188"
FT   REGION          1..32
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2..95
FT                   /note="Head"
FT   REGION          96..131
FT                   /note="Coil 1A"
FT   REGION          132..153
FT                   /note="Linker 1"
FT   REGION          154..245
FT                   /note="Coil 1B"
FT   REGION          246..268
FT                   /note="Linker 12"
FT   REGION          269..407
FT                   /note="Coil 2"
FT   REGION          408..466
FT                   /note="Tail"
FT   COILED          96..131
FT                   /evidence="ECO:0000269|PubMed:20176112"
FT   COILED          154..245
FT                   /evidence="ECO:0000269|PubMed:20176112"
FT   COILED          303..407
FT                   /evidence="ECO:0000269|PubMed:20176112"
FT   MOTIF           326..329
FT                   /note="[IL]-x-C-x-x-[DE] motif"
FT                   /evidence="ECO:0000305|PubMed:25417112"
FT   COMPBIAS        1..13
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        20..32
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            351
FT                   /note="Stutter"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0000269|Ref.13"
FT   MOD_RES         5
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:14762106,
FT                   ECO:0007744|PubMed:18669648"
FT   MOD_RES         7
FT                   /note="Phosphoserine; by PKA and PKC; alternate"
FT                   /evidence="ECO:0000269|PubMed:14762106"
FT   MOD_RES         8
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:14762106"
FT   MOD_RES         9
FT                   /note="Phosphoserine; by PKC"
FT                   /evidence="ECO:0000269|PubMed:14762106"
FT   MOD_RES         10
FT                   /note="Phosphoserine; by PKC"
FT                   /evidence="ECO:0000269|PubMed:14762106"
FT   MOD_RES         20
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         25
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         26
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         34
FT                   /note="Phosphoserine; by PKC; alternate"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         39
FT                   /note="Phosphoserine; by CaMK2, PKA, PKC and ROCK2"
FT                   /evidence="ECO:0000269|PubMed:14762106,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         42
FT                   /note="Phosphoserine; by PKC"
FT                   /evidence="ECO:0000269|PubMed:14762106,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         47
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         49
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         51
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         53
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P20152"
FT   MOD_RES         55
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P31000"
FT   MOD_RES         56
FT                   /note="Phosphoserine; by CDK5 and CDK1"
FT                   /evidence="ECO:0000269|PubMed:21465480, ECO:0000269|Ref.14,
FT                   ECO:0007744|PubMed:16964243, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         61
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         66
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         72
FT                   /note="Phosphoserine; by AURKB and ROCK2"
FT                   /evidence="ECO:0000269|PubMed:12458200,
FT                   ECO:0000269|PubMed:14762106, ECO:0007744|PubMed:18669648"
FT   MOD_RES         73
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:14762106,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         83
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:24275569"
FT   MOD_RES         87
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         117
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:15592455"
FT   MOD_RES         120
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         120
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P20152"
FT   MOD_RES         129
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P20152"
FT   MOD_RES         129
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P20152"
FT   MOD_RES         139
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         144
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692"
FT   MOD_RES         168
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P20152"
FT   MOD_RES         188
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P20152"
FT   MOD_RES         188
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P20152"
FT   MOD_RES         214
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         223
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P20152"
FT   MOD_RES         226
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         235
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P20152"
FT   MOD_RES         294
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P20152"
FT   MOD_RES         294
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P20152"
FT   MOD_RES         299
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         325
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P20152"
FT   MOD_RES         373
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         409
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         412
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:17924679, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:20068231"
FT   MOD_RES         419
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         420
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:14762106,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         426
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         430
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:14762106,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         436
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         438
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         445
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         445
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P20152"
FT   MOD_RES         446
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         458
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:14762106"
FT   MOD_RES         459
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:14762106,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   CARBOHYD        7
FT                   /note="O-linked (GlcNAc) serine; alternate"
FT                   /evidence="ECO:0000269|PubMed:20068230"
FT   CARBOHYD        33
FT                   /note="O-linked (GlcNAc) threonine"
FT                   /evidence="ECO:0000269|PubMed:20068230"
FT   CARBOHYD        34
FT                   /note="O-linked (GlcNAc) serine; alternate"
FT                   /evidence="ECO:0000269|PubMed:20068230"
FT   CROSSLNK        104
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        120
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        129
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        139
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        223
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        262
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        294
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        313
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        373
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        439
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        445
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        445
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:28112733"
FT   VARIANT         151
FT                   /note="E -> K (in CTRCT30; the mutation increases the
FT                   proteasome activity in transfected cells; also causes a
FT                   severe kinetic defect in vimentin assembly both in vitro
FT                   and in vivo; dbSNP:rs121917775)"
FT                   /evidence="ECO:0000269|PubMed:19126778"
FT                   /id="VAR_070100"
FT   VARIANT         208
FT                   /note="Q -> R (in CTRCT30; uncertain significance;
FT                   dbSNP:rs1085307141)"
FT                   /evidence="ECO:0000269|PubMed:28450710"
FT                   /id="VAR_078860"
FT   CONFLICT        42
FT                   /note="S -> D (in Ref. 1; AAA61279)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        113
FT                   /note="R -> P (in Ref. 12; CAA34499)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        197
FT                   /note="E -> G (in Ref. 6; CAG28618)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        201
FT                   /note="N -> S (in Ref. 17; AAA61281)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        265
FT                   /note="L -> S (in Ref. 17; AAA61281)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        278
FT                   /note="S -> I (in Ref. 17; AAA61281)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        339
FT                   /note="S -> C (in Ref. 17; AAA61281)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        350
FT                   /note="N -> K (in Ref. 17; AAA61281)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        442
FT                   /note="L -> F (in Ref. 1; AAA61279)"
FT                   /evidence="ECO:0000305"
FT   HELIX           101..135
FT                   /evidence="ECO:0007829|PDB:1GK7"
FT   HELIX           167..235
FT                   /evidence="ECO:0007829|PDB:4YPC"
FT   STRAND          238..241
FT                   /evidence="ECO:0007829|PDB:4YPC"
FT   TURN            244..248
FT                   /evidence="ECO:0007829|PDB:3UF1"
FT   HELIX           266..334
FT                   /evidence="ECO:0007829|PDB:3TRT"
FT   HELIX           385..405
FT                   /evidence="ECO:0007829|PDB:1GK6"
SQ   SEQUENCE   466 AA;  53652 MW;  BAB54026665B015A CRC64;
     MSTRSVSSSS YRRMFGGPGT ASRPSSSRSY VTTSTRTYSL GSALRPSTSR SLYASSPGGV
     YATRSSAVRL RSSVPGVRLL QDSVDFSLAD AINTEFKNTR TNEKVELQEL NDRFANYIDK
     VRFLEQQNKI LLAELEQLKG QGKSRLGDLY EEEMRELRRQ VDQLTNDKAR VEVERDNLAE
     DIMRLREKLQ EEMLQREEAE NTLQSFRQDV DNASLARLDL ERKVESLQEE IAFLKKLHEE
     EIQELQAQIQ EQHVQIDVDV SKPDLTAALR DVRQQYESVA AKNLQEAEEW YKSKFADLSE
     AANRNNDALR QAKQESTEYR RQVQSLTCEV DALKGTNESL ERQMREMEEN FAVEAANYQD
     TIGRLQDEIQ NMKEEMARHL REYQDLLNVK MALDIEIATY RKLLEGEESR ISLPLPNFSS
     LNLRETNLDS LPLVDTHSKR TLLIKTVETR DGQVINETSQ HHDDLE
//
